Physician profile
Nitin Bawa
NPI 1972536266
$17,696.18
in general payments reported to CMS, 2019-2025
51 companies · $940 in 2025
The $940 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $6,294 · 2021: $2,274 · 2022: $3,771 · 2023: $1,848 · 2024: $1,086 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,896 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,896.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $978.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,465.54 | 2019-2022 | |
| Merz North America, INC. | $3,317.09 | 2020-2025 | |
| Abbvie INC. | $1,900.37 | 2021-2025 | Botox, Qulipta, Vraylar |
| Lilly USA, LLC | $653.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $559.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $480.13 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Novo Nordisk INC | $456.28 | 2019-2024 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $376.97 | 2020-2023 | Austedo |
| Amgen INC. | $367.16 | 2019-2025 | Evenity, Prolia, Otezla |
| Merck Sharp & Dohme LLC | $286.89 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Lundbeck LLC | $251.54 | 2020-2025 | Vyepti, Rexulti |
| Idorsia Pharmaceuticals US INC | $215.64 | 2022-2025 | Quviviq, Quviviq |
| Eisai INC. | $213.98 | 2019-2022 | |
| Dexcom, INC. | $163.53 | 2021-2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $150.80 | 2024-2025 | Tirosint, Licart, Flector |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Bawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.